BALLIET JENNIFER 4
4 · NEOGENOMICS INC · Filed Aug 4, 2020
Insider Transaction Report
Form 4
BALLIET JENNIFER
Vice President of HR
Transactions
- Exercise/Conversion
Common Stock
2020-08-03$7.52/sh+13,000$97,760→ 37,980 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-08-03−13,000→ 7,000 totalExercise: $7.52Exp: 2022-04-28→ Common Stock (13,000 underlying) - Sale
Common Stock
2020-08-03$39.25/sh−13,000$510,250→ 24,980 total
Holdings
- 48,334
Stock Option (Right to Buy)
Exercise: $8.03Exp: 2023-02-26→ Common Stock (48,334 underlying) - 15,006
Stock Option (Right to Buy)
Exercise: $28.33Exp: 2027-03-02→ Common Stock (15,006 underlying) - 17,496
Stock Option (Right to Buy)
Exercise: $19.60Exp: 2024-03-01→ Common Stock (17,496 underlying)
Footnotes (4)
- [F1]On April 28, 2017, Ms. Balliet was granted 60,000 stock options. These options vest ratably over the first three anniversaries of the grant date.
- [F2]On February 26, 2018, Ms. Balliet was granted 72,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.
- [F3]On March 1, 2019, Ms. Balliet was granted 17,496 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- [F4]On March 2, 2020, Ms. Balliet was granted 15,006 stock options. These options vest ratably over the first four anniversary dates of the grant date.